Abstract: This invention generally relates to a method for promoting growth and increasing feed utilization efficiency in animals, and, more specifically, to combinations comprising zilpaterol (and salts thereof) and melengestrol acetate. Included within this invention are treatment methods comprising the administration of such combinations to animals, compositions comprising such combinations, uses of such combinations to prepare medicaments, and kits for using such combinations.

Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

Abstract: The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia, e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

Abstract: Production processes and systems are provided that include reacting halogenated compounds, dehalogenating compounds, reacting alcohols, reacting olefins and a saturated compounds, reacting reactants having at least two —CF3 groups with reactants having cyclic groups. RF-compositions such as RF-intermediates, RF-surfactants, RFmonomers, RF-monomer units, RF-metal complexes, RF-phosphate esters, RF-glycols, RF-urethanes, and/or RF-foam stabilizers. The RF portion can include at least two CF3 groups, at least three —CF3 groups, and/or at least two —CF3 groups and at least two —CH2— groups. Detergents, emulsifiers, paints, adhesives, inks, wetting agents, foamers, and defoamers including the RF-surfactant composition are provided. Acrylics, resins, and polymers are provided that include a RF-monomer unit. Compositions are provided that include a substrate having a RF-composition thereover.

Abstract: A magnetic assembly for mounting to a circuit includes a winding and a core. The winding has a first end, a second end and a wound portion. Further, the core is disposed around at least a portion of the winding. The first end of the winding extends outward from the wound portion to define a linear support and the second end of the winding extends outward from the wound portion on an opposite side of the wound portion to define a point support. As such, the first and second ends of the winding are adapted to mount to the circuit.

Abstract: A magnetic assembly for mounting to a circuit includes a winding and a core. The winding has a first end, a second end and a wound portion. Further, the core is disposed around at least a portion of the winding. The first end of the winding extends outward from the wound portion to define a linear support and the second end of the winding extends outward from the wound portion on an opposite side of the wound portion to define a point support. As such, the first and second ends of the winding are adapted to mount to the circuit.

Abstract: The present invention relates to an improved process for preparing 4-substituted resorcinol derivatives, and intermediate compounds useful in the preparation of such resorcinol derivatives.

Abstract: The present invention relates to an improved process for preparing 4-substituted resorcinol derivatives, and intermediate compounds useful in the preparation of such resorcinol derivatives.

Abstract: The present invention relates to an improved process for preparing 4-substituted resorcinol derivatives, and intermediate compounds useful in the preparation of such resorcinol derivatives.

Abstract: The present invention relates to an improved process for preparing 4-substituted resorcinol derivatives, and intermediate compounds useful in the preparation of such resorcinol derivatives.

Abstract: A three-way catalyst model (50) and a method for modeling the dynamic response of a three-way catalyst that divides the catalyst response into sub-regions (1-7) . A sub-model (44) is constructed that represents each sub-region (1-7) . Each sub-model (44) is assigned unique attributes at which the sub-model is activated. The attributes are based on the system parameters and states. The states may be either continuous or discrete and define a hybrid state space. A larger or smaller number of sub-regions (1-7) can be utilized based on the model's (50) use and the accuracy desired for the model (50).

Abstract: A method of controlling the air-fuel ratio of an internal combustion engine having an exhaust passage including a catalytic converter. The method includes providing a first air-fuel ratio sensor upstream of the catalytic converter, and providing a second air-fuel ratio sensor downstream of the catalytic converter. A control module having an input connected to the first and second air-fuel ratio sensors and an output connected to actuators for controlling the engine is also provided. This establishes a first feedback loop including the first air-fuel ratio sensor and a second feedback loop including the second air-fuel ratio sensor. The method further includes detecting an output value of the second air-fuel ratio indicative of a rich or lean exhaust gas air-fuel ratio. In response to the output value, the system monitors the engine mass airflow, and controls the duration of air-fuel ratio of the engine as a function of the engine mass airflow.